AcquisitionOther
Jazz Pharmaceuticals plc acquired Chimerix, Inc.
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Jazz Pharmaceuticals plc -> Chimerix, Inc. · approximately $935 million
To add dordaviprone, a novel first-in-class small molecule treatment for H3 K27M-mutant diffuse glioma, to Jazz's oncology portfolio and add near-term commercial opportunity to Jazz's pipeline
Open source record (SEC) ↗